[Denosumab for the treatment of solid tumor bone metástasis]
Hernández-Vásquez A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L.
Record ID 32015001156
Spanish
Authors' objectives:
To assess the available evidence on the efficacy, safety and coverage related aspects regarding BMST treatment.
Authors' recommendations:
The evidence found on the use of denosumab in bone metastases from solid tumors is of good methodological quality. Denosumab delays skeletal-related-events onset compared with zoledronic acid and the best support treatment in patients with bone metastases due to breast cancer, prostate and other solid tumors. However, no benefit has been observed in survival, bone pain and quality of life.
Some clinical practice guidance and coverage policies found, consider denosumab as an alternative to prevent SREs in the following tumors: breast, prostate, bladder, lung (NSCLC) and kidney. The NICE does not recommend it for prostate cancer since it does not provide enough benefit considering its high cost.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.iecs.org.ar/publicacion/?id=5338
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Humans
- Antibodies, Monoclonal, Humanized
- Bone Neoplasms
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.